Determining the economic value created by adding rituximab to chemotherapy in Canada
To determine the incremental cost (treatment and overall) of adding rituximab to existing chemotherapy and the value of life years saved in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic lymphoma (CLL).
RESEARCH QUESTIONS are as follows:
i) What is the survival (number of life years) for the R+Chemo (Cohort 1), Chemo alone historical cohort (Cohort 2a) and Chemo alone R-excluded cohorts (Cohort 2b)?
ii) What is the cost of care for the all three cohorts?
iii) What is the difference in life years between all three cohorts?
iv) What is the difference in cost (treatment and overall) between all three cohorts?
HYPOTHESES are as follows:
i) Survival will likely be greatest in the Cohort 1 followed by Cohort 2b and then Cohort 2a.
ii) Cost of care will likely be the greatest in the Cohort 1, followed by Cohort 2b and then Cohort 2a.
iii) There will be significant differences in life years between all the cohorts.
iv) There will be significant difference in costs between all the cohorts.